Amin Moqadami; Mohammad Khalaj-Kondori
Abstract
Long non-coding RNAs (lncRNAs) have recently emerged as effective regulatory agents in biological processes as well as in the formation of tumors. LncRNAs are important regulators of cell transformation and cancer progression. LncRNA NEAT1 is one of the most important lncRNAs, and its deregulation has ...
Read More
Long non-coding RNAs (lncRNAs) have recently emerged as effective regulatory agents in biological processes as well as in the formation of tumors. LncRNAs are important regulators of cell transformation and cancer progression. LncRNA NEAT1 is one of the most important lncRNAs, and its deregulation has been reported in a variety of human cancers. Ovarian cancer has an inverse relationship with the number of reported pregnancies and deliveries, while it has a direct relationship with infertility. This study aimed to investigate NEAT1 expression in ovarian cancer. A total of 140 tissue samples, including 70 ovarian tumors and 70 marginal samples, were included in the study. Total RNA was extracted using the RNXplus solution. The quality and quantity of the extracted RNAs were determined using gel electrophoresis and a NanoDrop device. The complementary DNA was synthesized by the reverse transcriptase enzyme, and quantitative reverse transcriptase PCR was used to quantify the expression of NEAT1. A comparison between the mean expression of NEAT1 in ovarian tumors and marginal samples showed an increase in NEAT1 expression in tumor tissue that was not statistically significant (P-value = 0.2). ROC curve analysis also showed that NEAT1 expression level might not be an informative biomarker for ovarian cancer.
Seyedeh Nahid Fotuhi; Mohammad Khalaj-Kondori; Hadis Karimi
Abstract
Patients with ovarian cancer are mostly diagnosed at advanced stages which leads to poor prognosis and high mortality rate. Deregulation of lncRNA HOXD-AS1 expression associates with cancer development and metastasis. However, the expression level of this lncRNA in ovarian cancer ...
Read More
Patients with ovarian cancer are mostly diagnosed at advanced stages which leads to poor prognosis and high mortality rate. Deregulation of lncRNA HOXD-AS1 expression associates with cancer development and metastasis. However, the expression level of this lncRNA in ovarian cancer is not determined.50paired ovarian tumors and their adjusted normal tissues were included in the study. Total RNA was extracted by TRIzol® Reagent and reverse-transcribed to cDNA using PrimeScript II cDNA synthesis kit. The expression levels of HOXD-AS1 were quantified by qRT-PCR and compared. The Roc curve analysis was used to evaluate the capacity of HOXD-AS1 as a biomarker for ovarian cancer. We observed that lncRNA HOXD-AS1 was significantly upregulated in ovarian tumors compared to their adjusted normal tissues (p <0.003). Moreover, the ROC curve analysis revealed that the lncRNA HOXD-AS1 expression level could discriminate tumoral and non-tumoral tissues with 85% sensitivity and 88% specificity. The lncRNA HOXD-AS1 expression level might be considered as a potential biomarker for ovarian cancer development.
Maryam Rezaeigazik; Mohammad Nabiuni; Hanieh Jalali; Majid Kabuli
Abstract
Morphine as an analgesic drug is used frequently in cancer patients. Contradictory results have been achieved from previous studies related to morphine effects in different concentrations. In current study, we examined the effect of clinical concentrations of morphine on A2780Cp cell line related to ...
Read More
Morphine as an analgesic drug is used frequently in cancer patients. Contradictory results have been achieved from previous studies related to morphine effects in different concentrations. In current study, we examined the effect of clinical concentrations of morphine on A2780Cp cell line related to ovarian cancer. Moreover, its effect on the cytotoxicity of cisplatin was investigated. A2780CP cells were cultured in RPMI1640 medium and treated with clinical doses of morphine alone or in combination with cisplatin. The rate of cell proliferation was measured using MTT assay, morphological changes of nuclei were revealed by 4′,6-diamidino-2-phenylindole (DAPI) staining, and expression of B-cell lymphoma 2 (Bcl-2) was measured using flowcytometry. MTT assay results showed clinical concentration of morphine had no effect on viability of A2780CP cells and toxicity of cisplatin. DAPI staining revealed no chromatin condensation in presence of morphine, and flowcytometry analysis showed that the expression of Bcl-2 in treated cells did not differ from control cells. In accordance with findings in other kinds of cancer, our results demonstrated that morphine did not interact with the function of cispatin in ovarian cancer. This finding can be considered in clinical applications of morphine.
